What is Synjardy
MetforminThe Generic name of this drug
Treatment SummaryMetformin is a medication used to treat type 2 diabetes. It is the first-line drug of choice for managing type 2 diabetes and is taken by more than 120 million people around the world. Metformin lowers blood sugar levels without causing hypoglycemia, increases insulin sensitivity, and leads to modest weight loss. It was first approved in Canada in 1972 and in the United States in 1995. Metformin is available in regular and extended-release form.
Metformin Hydrochlorideis the brand name
Synjardy Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Metformin Hydrochloride
Metformin
2002
1266
Approved as Treatment by the FDA
Metformin, otherwise known as Metformin Hydrochloride, is approved by the FDA for 21 uses which include Type 1 Diabetes and Ejection fraction decreased .Type 1 Diabetes
Used to treat Type 1 Diabetes Mellitus in combination with Sitagliptin
Ejection fraction decreased
Used to treat Ejection fraction decreased in combination with Dapagliflozin
Cardiovascular Diseases
Used to treat established cardiovascular disease in combination with Dapagliflozin
Congestive Heart Failure
Used to treat Heart Failure in combination with Dapagliflozin
Physical Activity
Used to treat Exercise in combination with Dapagliflozin
Diet
Used to treat Diet in combination with Dapagliflozin
Chronic Kidney Disease
Used to treat Chronic Kidney Disease (CKD) in combination with Dapagliflozin
Cardiovascular Disease
Used to treat Cardiovascular Risk in combination with Dapagliflozin
Hospitalizations
Used to treat Hospitalizations in combination with Dapagliflozin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Dapagliflozin
uncontrolled diabetes
Used to treat uncontrolled diabetes in combination with Rosiglitazone
NYHA Functional Class II-IV Heart Failure
Used to treat NYHA Functional Class II-IV Heart Failure in combination with Dapagliflozin
inadequate response to sulfonylurea
Used to treat inadequate response to sulfonylurea in combination with Vildagliptin
inadequate response to metformin
Used to treat inadequate response to metformin in combination with Vildagliptin
diet and exercise
Used to treat diet and exercise in combination with Vildagliptin
inadequate response to recombinant human insulin
Used to treat inadequate response to recombinant human insulin in combination with Vildagliptin
Kidney Failure
Used to treat End Stage Renal Disease (ESRD) in combination with Dapagliflozin
Diabetic Ketoacidosis
Used to treat Diabetic Ketoacidosis in combination with Saxagliptin
Cardiovascular Mortality
Used to treat Cardiovascular Mortality in combination with Dapagliflozin
decreased estimated glomerular filtration rate
Used to treat decreased estimated glomerular filtration rate in combination with Dapagliflozin
Pharmaceutical Preparations
Used to treat previously treated with drugs in combination with Vildagliptin
Effectiveness
How Synjardy Affects PatientsInsulin is a hormone that helps control the amount of sugar in the blood. People with Type II diabetes have a decreased sensitivity to insulin, which means their pancreas cannot keep up with regulating their sugar levels. Metformin works to reduce the amount of sugar produced by the liver and absorbed by the intestines, as well as increase the body's sensitivity to insulin. In a clinical trial, people taking Metformin had decreased fasting blood sugar levels by an average of 59 mg/dL, while those taking a placebo had increased levels by 6.3 mg/dL. Metformin also decreased HbA1c by 1
How Synjardy works in the bodyMetformin works in several ways to reduce blood glucose levels. It decreases the amount of glucose produced in the liver, decreases the amount of glucose absorbed from food in the intestines, and makes cells more sensitive to insulin. Metformin enters liver cells through a transporter called OCT1, and accumulates in the mitochondria. It blocks the production of energy in the mitochondria, turning on an enzyme called AMPK. This helps to decrease fat production and increase fat burning, as well as reduce glucose production in the liver. In the intestines, metformin increases anaerobic glucose metabolism, leading to less net glucose uptake and
When to interrupt dosage
The suggested dose of Synjardy is contingent upon the recognized disorder, including Diet, inadequate response to metformin and Diabetic Ketoacidosis. The quantity differs, in line with the methodology of delivery (e.g. Oral or Tablet - Oral) listed in the table below.Condition
Dosage
Administration
Type 2 Diabetes
, 500.0 mg, 750.0 mg, 250.0 mg, 1000.0 mg, 850.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg, 625.0 mg, 0.5 mg/mg, 0.05 mg/mg
Oral, Tablet - Oral, , Tablet, film coated - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet, film coated, Kit, Tablet, film coated, extended release, Tablet, extended release - Oral, Solution, Tablet, coated, Kit - Oral, Solution - Oral, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral
Type 1 Diabetes
, 500.0 mg, 750.0 mg, 250.0 mg, 1000.0 mg, 850.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg, 625.0 mg, 0.5 mg/mg, 0.05 mg/mg
Oral, Tablet - Oral, , Tablet, film coated - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet, film coated, Kit, Tablet, film coated, extended release, Tablet, extended release - Oral, Solution, Tablet, coated, Kit - Oral, Solution - Oral, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral
Polycystic Ovarian Syndrome
, 500.0 mg, 750.0 mg, 250.0 mg, 1000.0 mg, 850.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg, 625.0 mg, 0.5 mg/mg, 0.05 mg/mg
Oral, Tablet - Oral, , Tablet, film coated - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet, film coated, Kit, Tablet, film coated, extended release, Tablet, extended release - Oral, Solution, Tablet, coated, Kit - Oral, Solution - Oral, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral
Physical Activity
, 500.0 mg, 750.0 mg, 250.0 mg, 1000.0 mg, 850.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg, 625.0 mg, 0.5 mg/mg, 0.05 mg/mg
Oral, Tablet - Oral, , Tablet, film coated - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet, film coated, Kit, Tablet, film coated, extended release, Tablet, extended release - Oral, Solution, Tablet, coated, Kit - Oral, Solution - Oral, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral
uncontrolled diabetes
, 500.0 mg, 750.0 mg, 250.0 mg, 1000.0 mg, 850.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg, 625.0 mg, 0.5 mg/mg, 0.05 mg/mg
Oral, Tablet - Oral, , Tablet, film coated - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet, film coated, Kit, Tablet, film coated, extended release, Tablet, extended release - Oral, Solution, Tablet, coated, Kit - Oral, Solution - Oral, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral
inadequate response to metformin
, 500.0 mg, 750.0 mg, 250.0 mg, 1000.0 mg, 850.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg, 625.0 mg, 0.5 mg/mg, 0.05 mg/mg
Oral, Tablet - Oral, , Tablet, film coated - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet, film coated, Kit, Tablet, film coated, extended release, Tablet, extended release - Oral, Solution, Tablet, coated, Kit - Oral, Solution - Oral, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral
Diabetic Ketoacidosis
, 500.0 mg, 750.0 mg, 250.0 mg, 1000.0 mg, 850.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg, 625.0 mg, 0.5 mg/mg, 0.05 mg/mg
Oral, Tablet - Oral, , Tablet, film coated - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet, film coated, Kit, Tablet, film coated, extended release, Tablet, extended release - Oral, Solution, Tablet, coated, Kit - Oral, Solution - Oral, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral
diet and exercise not sufficient for diabetes control
, 500.0 mg, 750.0 mg, 250.0 mg, 1000.0 mg, 850.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg, 625.0 mg, 0.5 mg/mg, 0.05 mg/mg
Oral, Tablet - Oral, , Tablet, film coated - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet, film coated, Kit, Tablet, film coated, extended release, Tablet, extended release - Oral, Solution, Tablet, coated, Kit - Oral, Solution - Oral, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral
Diet
, 500.0 mg, 750.0 mg, 250.0 mg, 1000.0 mg, 850.0 mg, 500.0 mg/mL, 660.0 mg, 780.0 mg, 625.0 mg, 0.5 mg/mg, 0.05 mg/mg
Oral, Tablet - Oral, , Tablet, film coated - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet, film coated, Kit, Tablet, film coated, extended release, Tablet, extended release - Oral, Solution, Tablet, coated, Kit - Oral, Solution - Oral, Tablet, coated - Oral, For suspension, extended release, For suspension, extended release - Oral
Warnings
Synjardy ContraindicationsCondition
Risk Level
Notes
Acute Coryza
Do Not Combine
Liver Failure
Do Not Combine
Metabolic acidosis
Do Not Combine
Lactic Acidosis
Do Not Combine
ethanol
Do Not Combine
cardiorespiratory insufficiency caused by Heart Failure
Do Not Combine
Hypovolemic Shock
Do Not Combine
cardiovascular collapse
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Hypoxemia
Do Not Combine
Impaired Renal Function
Do Not Combine
serum creatinine above upper limit for age range
Do Not Combine
Impaired Renal Function
Do Not Combine
kidney function unknown
Do Not Combine
estimated GFR <30mL/min
Do Not Combine
severe hepatic dysfunction
Do Not Combine
Comatose
Do Not Combine
Traumatic Injury
Do Not Combine
Impaired Renal Function
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Metformin may interact with Toxoplasma Infections
Common Synjardy Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Metformin.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Metformin.
Topotecan
Major
The excretion of Topotecan can be decreased when combined with Metformin.
Abacavir
Minor
Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Synjardy Toxicity & Overdose RiskThe toxic dose of metformin in rats is 1000mg/kg when taken orally, 500mg/kg when given through the abdomen, and 300mg/kg when injected under the skin. The toxic dose in mice is 1450mg/kg orally, 420mg/kg through the abdomen, and 225mg/kg when injected under the skin. Taking too much metformin can lead to lactic acidosis, a serious condition where too much acid builds up in the blood. Risk factors for lactic acidosis include kidney problems, being over 65 years old, taking certain medications, drinking too much alcohol, or having liver disease
Synjardy Novel Uses: Which Conditions Have a Clinical Trial Featuring Synjardy?
346 active trials are assessing the potential of Synjardy in treating Type 2 Diabetes, Type 1 Diabetes and inadequate response to Metformin therapy.Condition
Clinical Trials
Trial Phases
Type 1 Diabetes
140 Actively Recruiting
Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 2, Phase 4
Type 2 Diabetes
176 Actively Recruiting
Phase 2, Not Applicable, Phase 4, Early Phase 1, Phase 1, Phase 3
diet and exercise not sufficient for diabetes control
0 Actively Recruiting
inadequate response to metformin
0 Actively Recruiting
Diet
4 Actively Recruiting
Not Applicable
Polycystic Ovarian Syndrome
9 Actively Recruiting
Phase 1, Phase 3, Phase 2, Early Phase 1, Phase 4, Not Applicable
Physical Activity
37 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1
Diabetic Ketoacidosis
2 Actively Recruiting
Phase 2
uncontrolled diabetes
0 Actively Recruiting
Synjardy Reviews: What are patients saying about Synjardy?
5Patient Review
10/17/2018 Synjardy has been great for me. I brought my A1C down from 10.6 to 6.0 in a year, and experienced zero negative side effects.
4Patient Review
4/17/20164Patient Review
11/9/20172.3Patient Review
1/30/2019 My A1C rose from 6.5 to 8.7 after my doctor switched me from Farxiga to Synjardy. I found the latter drug much less effective than the former.
2Patient Review
9/4/2018 I unfortunately got a yeast infection from this medication.
1.7Patient Review
5/12/2019 Thirst, yeast infection, and constant trips to the bathroom are all unfortunately common side effects of this medication. I've been taking it for five months now and have had to deal with a lot of discomfort as a result.
1Patient Review
9/9/2018 I was worried from the start with this prescription. My blood sugar shot up, and even when I increased the dose as directed, it didn't seem to be effective.
1Patient Review
9/8/2021 I was in a lot of pain after injuring my knee and was prescribed Synjardy. However, this medication caused me more pain and fatigue than the original injury. I stopped taking it and felt better the next day.
Patient Q&A Section about synjardy
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Synjardy used for?
"This medication is a combination of 2 drugs: empagliflozin and metformin. It is used with a proper diet and exercise program to lower blood sugar in people with type 2 diabetes. Controlling blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems."
Answered by AI
What is the side effects of Synjardy?
"Some possible causes of these symptoms include low blood sugar, a urinary tract infection, a stuffy or runny nose and sore throat, yeast infections in females, diarrhea, nausea or vomiting, gas, stomach discomfort, indigestion, weakness, or a headache."
Answered by AI
What is the difference between Synjardy and metformin?
"Synjardy contains both metformin and the drug empagliflozin. Metformin lowers blood sugar levels through several mechanisms, and the addition of empagliflozin provides additional blood sugar lowering effects."
Answered by AI
Are Jardiance and Synjardy the same thing?
"Jardiance is a medication used to treat type 2 diabetes. It is available as a standalone tablet or as a combination tablet with metformin. The medication works by helping the body to better use insulin. Side effects may include nausea, diarrhea, and headaches. Jardiance is a brand-name medication and costs can vary depending on insurance coverage."
Answered by AI